scholarly article | Q13442814 |
P356 | DOI | 10.1136/GUTJNL-2012-302062 |
P698 | PubMed publication ID | 22504919 |
P2093 | author name string | Karine Lacombe | |
Juergen Rockstroh | |||
P407 | language of work or name | English | Q1860 |
P921 | main subject | viral hepatitis | Q1983841 |
P304 | page(s) | i47-58 | |
P577 | publication date | 2012-05-01 | |
P1433 | published in | Gut | Q5621669 |
P1476 | title | HIV and viral hepatitis coinfections: advances and challenges | |
P478 | volume | 61 Suppl 1 |
Q36732492 | A Cross Section Study to Determine the Prevalence of Antibodies against HIV Infection among Hepatitis B and C Infected Individuals |
Q39037936 | An effective interferon-gamma-mediated inhibition of hepatitis C virus replication by natural killer cells is associated with spontaneous clearance of acute hepatitis C in human immunodeficiency virus-positive patients. |
Q28534869 | CCR5 haplotypes influence HCV serostatus in Caucasian intravenous drug users |
Q30382346 | Chronic viral hepatitis: policy, regulation, and strategies for its control and elimination in Ethiopia |
Q54243856 | Consequence of HIV and HCV co-infection on host immune response, persistence and current treatment options. |
Q38675898 | Cross-Sectional Study to Determine the Prevalence of Hepatitis B and C Virus Infection in High Risk Groups in the Northeast Region of Brazil. |
Q43065380 | Curative effect of hepatic portal venous administration of autologous bone marrow in AIDS patients with decompensated liver cirrhosis |
Q28548313 | Detection of Hepatitis B Virus (HBV) Genomes and HBV Drug Resistant Variants by Deep Sequencing Analysis of HBV Genomes in Immune Cell Subsets of HBV Mono-Infected and/or Human Immunodeficiency Virus Type-1 (HIV-1) and HBV Co-Infected Individuals |
Q36783264 | Different faces of hepatocellular carcinoma as a health threat in 21st century |
Q26786103 | Early-life exposures to infectious agents and later cancer development |
Q52642614 | Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Co-infected with Hepatitis C Virus and Human Immunodeficiency Virus-1: the EXPEDITION-2 Study. |
Q40481513 | Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. |
Q36698116 | Epidemiological, virological and clinical characteristics of HBV infection in 223 HIV co-infected patients: a French multi-centre collaborative study |
Q90364811 | Establishment of the Dual Humanized TK-NOG Mouse Model for HIV-associated Liver Pathogenesis |
Q38204769 | Future considerations for dendritic cell immunotherapy against chronic viral infections |
Q36015496 | HIV Infection Status as a Predictor of Hepatitis C Virus RNA Testing in Primary Care |
Q34977282 | HIV and HCV coinfection: prevalence, associated factors and genotype characterization in the Midwest Region of Brazil |
Q46317637 | HIV and hepatitis B and C co-infection among people who inject drugs in Zanzibar |
Q35033499 | HIV virological rebounds but not blips predict liver fibrosis progression in antiretroviral-treated HIV/hepatitis C virus-coinfected patients. |
Q38918596 | Hepatitis B surface antigen quantification as a predictor of seroclearance during treatment in HIV-hepatitis B virus coinfected patients from Sub-Saharan Africa |
Q36293979 | Hepatitis B virus sub-genotype A1 infection is characterized by high replication levels and rapid emergence of drug resistance in HIV-positive adults receiving first-line antiretroviral therapy in Malawi |
Q36083688 | Hepatitis C treatment initiation in HIV-HCV coinfected patients |
Q42207980 | High HCV treatment uptake in the Swedish HIV/HCV co-infected cohort |
Q36268801 | High Prevalence and High Incidence of Coinfection with Hepatitis B, Hepatitis C, and Syphilis and Low Rate of Effective Vaccination against Hepatitis B in HIV-Positive Men Who Have Sex with Men with Known Date of HIV Seroconversion in Germany |
Q37415420 | Human hepatocytes and hematolymphoid dual reconstitution in treosulfan-conditioned uPA-NOG mice. |
Q39503010 | Impact of hepatitis B on mortality and specific causes of death in adults with and without HIV co-infection in NYC, 2000-2011. |
Q30364549 | Infection of female primary lower genital tract epithelial cells after natural pseudotyping of HIV-1: possible implications for sexual transmission of HIV-1. |
Q40590338 | Intensification with pegylated interferon during treatment with tenofovir in HIV-hepatitis B virus co-infected patients |
Q42669311 | Lack of a clinically significant drug-drug interaction in healthy volunteers between the hepatitis C virus protease inhibitor boceprevir and the HIV integrase inhibitor raltegravir |
Q39491769 | Liver Fibrosis by Transient Elastography and Virologic Outcomes After Introduction of Tenofovir in Lamivudine-Experienced Adults With HIV and Hepatitis B Virus Coinfection in Ghana |
Q35664183 | Management of chronic hepatitis B in patients from special populations |
Q35042619 | Managing HIV/hepatitis C co-infection in the era of direct acting antivirals |
Q44324472 | Morbidity and mortality in HIV infection |
Q27006027 | New agents for the treatment of hepatitis C in patients co-infected with HIV |
Q40899794 | New hepatitis C therapies for special patient populations |
Q38295822 | Optimal therapy of HIV/HCV co-infected patients with direct acting antivirals |
Q40343820 | Performance of ANTI-HCV testing in dried blood spots and saliva according to HIV status |
Q42223115 | Persistent viremia in human immunodeficiency virus/hepatitis B coinfected patients undergoing long-term tenofovir: virological and clinical implications |
Q41528360 | Persistently elevated abnormal B-cell subpopulations and anti-core antibodies in patients co-infected with HIV/HCV who relapse |
Q39613730 | Prevalence and Determinants of Cryptosporidium Infection in an Underdeveloped Rural Region of Southwestern China |
Q40040535 | Prevalence of hepatitis D virus infection in sub-Saharan Africa: a systematic review and meta-analysis |
Q37272968 | Primary care of women aging with HIV. |
Q41929282 | Profile of HIV subtypes in HIV/HBV- and HIV/HCV-coinfected patients in Southern Brazil |
Q33594879 | Pros and cons of liver transplantation in human immunodeficiency virus infected recipients |
Q91862651 | Risk of Liver Fibrosis in Hepatitis B Virus and HIV Coinfected Youths Receiving Tenofovir-Containing Antiretroviral Regimen |
Q36550395 | Sero-prevalence of HBV and associated risk factors among HIV positive individuals attending ART clinic at Mekelle hospital, Tigray, Northern Ethiopia |
Q64101170 | Sero-prevalence of Hepatitis B and C viral co-infections among HIV-1 infected ART-naïve individuals in Kumasi, Ghana |
Q37111444 | Short communication: Interferon/ribavirin treatment for HCV is associated with the development of hypophosphatemia in HIV/hepatitis C virus-coinfected patients |
Q26740233 | Spotlight on grazoprevir-elbasvir once-daily combination and its potential in the treatment of hepatitis C |
Q34981656 | Strategy to better select HIV-infected individuals for latent TB treatment in BCG-vaccinated population |
Q21559628 | The burgeoning HIV/HCV syndemic in the urban Northeast: HCV, HIV, and HIV/HCV coinfection in an urban setting |
Q54725550 | The γ-glutamyl transpeptidase-to-platelet ratio as a predictor of liver fibrosis in patients co-infected with HBV and HIV. |
Q37620340 | Treatment of Hepatitis B: A Concise Review |
Q38119893 | Update on HIV/HCV coinfection. |
Q42233095 | Use of hepatitis B surface and "e" antigen quantification during extensive treatment with tenofovir in patients co-infected with HIV-HBV. |
Q39147842 | Vaccination against hepatitis B virus among people who inject drugs - A 20year experience from a Swedish needle exchange program |
Q38203823 | Viral hepatitis C therapy: pharmacokinetic and pharmacodynamic considerations |
Q36821936 | Viral hepatitis in resource-limited countries and access to antiviral therapies: current and future challenges. |
Search more.